June 2016 - Antwerp, Belgium

Meeting objectives: 

  • To review cultural, infrastructural and financial barriers that impact implementation of vaccination and screening programmes. 
  • To review the adverse events profile following HPV vaccination.
  • To update the points of view regarding safety issues and describe new developments.
  • To discuss the impact of safety issues and crises in an international perspective.
  • To review factors impacting adherence to cervical screening programmes.
  • To learn from country initiatives in HPV vaccine safety monitoring and HPV screening adherence.
  • To propose strategies to counter vaccination and screening hesitancy and to build public confidence in the HPV prevention programs
  • To discuss a new approach to implement HPV prevention and control: HPV-Faster. 

 (pdf, 2.34 MB)

June 27, 2016

SESSION 1: OPENING
Chairs: Lauri Markowitz & Pierre Van Damme

  •  (pdf, 675 KB)
    Alex Vorsters, University of Antwerp

SESSION 2: INTERPRETATION OF SAFETY DATA
Chairs: Lauri Markowitz & Pierre Van Damme

  •  (pdf, 2.01 MB)
    Robert Pless, Public Health Agency of Canada GACVS
  •  (pdf, 1.25 MB)
    Pier Luigi Lopalco, University of Pisa (Italy)
  •  (pdf, 931 KB)
    Hannah Nohynek, National Institute for Health and Welfare (Finland)
  • Vaccine safety - Mortality after HPV vaccination observed in RCTs
    Marc Arbyn, Scientific Institute of Public Health (Belgium)
  • Questions & Discussion​

SESSION 3: VACCINE CONFIDENCE 
Chairs: Pier Luigi Lopalco & Monica Chaturvedi

  •  (pdf, 3.58 MB)
    Heidi Larson and Emilie Karafillakis, London School of Hygiene and Tropical Medicine (UK)
  • Questions and Discussion
  •  (pdf, 3.07 MB)
    Heidi Larson and Emilie Karafillakis
  • Questions & Discussion​

SESSION 4: HPV VACCINATION PROGRAMS: COUNTRY EXPERIENCES AND LESSONS LEARNT
Chairs: Margaret Stanley & Joakim Dillner

  •  (pdf, 1.49 MB)
    Kevin Pollock, Health Protection Scotland
  •  (pdf, 1.88 MB)
    Monica Chaturvedi, Public Health Foundation (India)
  • The Japanese HPV vaccine tragedy and the take-home message
    Sharon Hanley, Hokkaido University Graduate School of Medicine (Japan)
  •  (pdf, 2.36 MB)
    Joanne Yarwood, National Infection Service, Public Health England (UK)
  •  (pdf, 1.61 MB)
    Lauri Markowitz, Centre for Disease Control & Prevention (CDC) (US)
  •  (pdf, 1.46 MB)
    Geert Top, Flemish Agency for Care and Health (Belgium))
  • Questions & Discussion​

SESSION 4: HPV VACCINATION PROGRAMS: COUNTRY EXPERIENCES AND LESSONS LEARNT (³¦´Ç²Ô³Ù’d)
Chairs: Mira Kojouharova & Paolo Bonanni

  •  (pdf, 1.16 MB)
    Patriciu Achimas, The Oncology Institute "Prof. Dr. Ion Chiricuta" (Romania)
  •  (pdf, 2.99 MB)
    Kate Gallagher (presenting on behalf of Deborah Watson-Jones), London school of Hygiene and Tropical Medicine (UK)
  •  (pdf, 1.40 MB)
    Xavier Bosch, Catalanian Institute of Ocology (Spain)
  • Questions & Discussion

June 28, 2016

SESSION 4: HPV VACCINATION PROGRAMS: COUNTRY EXPERIENCES AND LESSONS LEARNT (³¦´Ç²Ô³Ù’d)
Chairs: Liudmila Mosina & Mario Poljak

  •  (pdf, 1.93 MB)
    Kåre Mølbak, Statens Serum Institute, Division of Epidemiology and Disease Surveillance (Denmark)

SESSION 5: BARRIERS AND OPPORTUNITIES IN HPV SCREENING PROGRAMS 

  •  (pdf, 1.54 MB)
    Laura Marlow, Department of Epidemiology and Public Health, UCL (UK)
  •  (pdf, 1.53 MB)
    Scott Wittet, PATH (US)
  •  (pdf, 2.24 MB)
    Pamela Wakewich, Lakehead University (Canada)
  •  (pdf, 424 KB)
    Patriciu Achimas, The Oncology Institute "Prof. Dr. Ion Chiricuta" (Romania)
  • Questions & Discussion​

SESSION 6: HPV-FASTER: BROADENING THE SCOPE FOR PREVENTION OF HPV-RELATED CANCER
Chairs: Susan Wang & Marc Arbyn

  •  (pdf, 1.75 MB)
    Xavier Bosch Catalanian Institute of Ocology (Spain)
  •  (pdf, 945 KB)
    Silvia de Sanjose, Catalanian Institute of Ocology (Spain)
  •  (pdf, 1.66 MB)
    Iacopo Baussano, International Agency (France)

SESSION 7: CONCLUSION OF THE MEETING
Chairs: Mark Kane & Xavier Bosch

  •  (pdf, 532 KB)
    Marc Baay